03/24/2021 | Press release | Archived content
March 24, 2021
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Jordan Metoyer and Ada D. Sarmento
Re: | Marrone Bio Innovations, Inc. |
Registration Statement on Form S-3 | |
Filed on February 8, 2021 | |
File No. 333-252823 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Marrone Bio Innovations, Inc. (the 'Registrant') hereby requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-252823) to 4:00 p.m., Eastern Time, on March 26, 2021, or as soon as practicable thereafter.
The Registrant requests that it be notified of such effectiveness by contacting Alfredo B. D. Silva, the Company's counsel at Morrison & Foerster LLP, at (415) 268-6213 or [email protected].
Very truly yours, | ||
Marrone Bio Innovations, Inc. | ||
By: | /s/ Kevin Helash | |
Name: | Kevin Helash | |
Title: | Chief Executive Officer |